

UNITED STATES DEPARTMENT OF COMMERCY United States Patent and Trademark Offide Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/534,128	05/06/2005	Mi-Chung Suh	ZEN-0002	2798
34610 KED & ASSO	7590 03/22/2007		EXAMINER	
P.O. Box 2212	00		BAGGOT, BRENDAN O	
Chantilly, VA 20153-1200			ART UNIT	PAPER NUMBER
•			1638	
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
31 [	DAYS	03/22/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)				
	10/534,128	SUH ET AL.				
Office Action Summary	Examiner	Art Unit				
· · · · · · · · · · · · · · · · · · ·						
The MAILING DATE of this communication ap	Brendan O. Baggot  pears on the cover sheet with	h the correspondence address				
Period for Reply		•				
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D  - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUNIC 136(a). In no event, however, may a rej will apply and will expire SIX (6) MONT e, cause the application to become ABA	ATION. ply be timely filed  HS from the mailing date of this communication. INDONED (35 U.S.C. § 133).				
Status		•				
1) Responsive to communication(s) filed on 13 /	March 2005.					
2a) This action is <b>FINAL</b> . 2b) ☑ This	s action is non-final.	·				
3) Since this application is in condition for allowa	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under	Ex parte Quayle, 1935 C.D.	11, 453 O.G. 213.				
Disposition of Claims						
4) ⊠ Claim(s) 1-11 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-11 are subject to restriction and/or	awn from consideration.					
Application Papers						
9) The specification is objected to by the Examin	er.					
10)☐ The drawing(s) filed on is/are: a)☐ acc	cepted or b)□ objected to b	y the Examiner.				
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E		•				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat* See the attached detailed Office action for a list	nts have been received. Its have been received in Appority documents have been reule (PCT Rule 17.2(a)).	oplication No received in this National Stage				
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	Paper No(s)	ummary (PTO-413) /Mail Date formal Patent Application (PTO-152) -				

Application/Control Number: 10/534,128

Art Unit: 1638

## **DETAILED ACTION**

## Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-2, 4-11 drawn to a promoter: SEQ ID NO: 3.

Group II, claim(s) 3-11drawn to an intron: SEQ ID NO: 1

- i. Vector pBinS/FAD2-GUS
- ii. Vector pSiW6-P2.4

In addition to I or II above, applicant must further elect i. OR ii.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions are linked by the technical feature of a seed specific promoter. However, this technical feature is not special because it does not constitute an advance over the prior art. There are numerous examples of seed-specific expression of seed storage protein genes in transgenic dicotyledonous and monocotyledonous plants. (See US-5530186; Hitz et al, column 13, 3<sup>rd</sup> paragraph).

Furthermore, the invention of Group I, a first product, requires a single copy of SEQ ID NO: 3 only, each not required by any other Group.

Art Unit: 1638

Furthermore, the invention of Group II, a first product, requires a single copy of SEQ ID NO: 1 only, each not required by any other Group.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicants are reminded that nucleotide sequences encoding different proteins or comprising different regulatory sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C. 121.

Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq.

Applicant is required to select a single nucleotide sequence. This requirement is not to be construed as a requirement for an election of species, since each nucleotide sequence is not a member of single genus of invention, but constitutes an independent and patentably distinct invention.

Art Unit: 1638

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brendan O. Baggot whose telephone number is 571/272-5265. The examiner can normally be reached on Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571/272-0975. The fax phone number for the organization where this application or

proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Brendan O. Baggot Patent Examiner

Art Unit 1638

Phuong Bui

Primary Examiner

Art Unit 1638

bob